BORDER LINES: F-H wins new Glaxo drug PR

WASHINGTON DC: Glaxo Wellcome has handed a six-figure assignment to promote its new irritable bowel syndrome (IBS) treatment Lotronex to Fleishman-Hillard. Marilyn Castaldi, senior partner and director of F-H’s healthcare practice, said the agency aims to raise consumer awareness of IBS and the fact that it can be easily treated. She added that F-H’s efforts, split between New York and Washington, will mainly target women, who are more commonly affected by IBS than men.

WASHINGTON DC: Glaxo Wellcome has handed a six-figure assignment to

promote its new irritable bowel syndrome (IBS) treatment Lotronex to

Fleishman-Hillard. Marilyn Castaldi, senior partner and director of

F-H’s healthcare practice, said the agency aims to raise consumer

awareness of IBS and the fact that it can be easily treated. She added

that F-H’s efforts, split between New York and Washington, will mainly

target women, who are more commonly affected by IBS than men.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in